SOURCE: Wall Street Equity Research

Wall Street Equity Research

January 28, 2011 08:39 ET

Small-Cap Research on Immunosyn Corporation and Neuralstem Inc. - Biotech Firms Continue Search for Next Big Drug Breakthrough

JOHANNESBURG, SOUTH AFRICA--(Marketwire - January 28, 2011) - gives shareholders valuable insight on biotechnology stocks Immunosyn Corporation (OTCBB: IMYN) and Neuralstem Inc. (NYSE Amex: CUR). Sign up today at to receive free research reports on these equities.

Companies operating in the Biotechnology sector spend most of the time and money developing potential cures for today's ailments and seeking FDA approval to continue their efforts through various tests. The process can be extremely expensive, and those unable to obtain funding are often left by the wayside. Visit us at to understand the catalysts and forces driving or affecting the biotechnology industry in today's economic environment. is a specialized website where investors can have specific access to free reports biotechnology industry; traders looking for analyst opinions on Immunosyn Corporation, Neuralstem Inc. and other companies in this industry are welcomed to sign up for a free one year membership at

One company that has proved itself, at least to the FDA, is Neuralstem Inc. The company which has an ongoing phase I clinical trial for the testing of its spinal cord stems cells in the treatment of Lou Gerhig's disease, has also recently received FDA approval to start phase I tests of its NSI-189 product. The NSI-189 product is being tested in the treatment of major depression. The company has also received government funding in excess of $700,000 through the Patient Protection and Affordable Care Act and has stated they will be using the money to further their research. Traders can get direct and free access to today's full report on Immunosyn Corporation by signing up at

While Neuralstem has had some success, the road has been much harder for Immunosyn Corp. The company is struggling to raise funds to continue their operations and the development of their SF-1019 product which is designed to treat a variety of ailments. The company has currently not obtained regulatory approval. Traders can have complimentary access to today's complete research report on Neuralstem Inc. by signing up at

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information